Results 301 to 310 of about 4,863,715 (431)
CD28 shapes T cell receptor signaling by regulating Lck dynamics and ZAP70 activation. [PDF]
Raychaudhuri K+9 more
europepmc +1 more source
Pseudomonas exotoxin-anti-TAC. Cell-specific immunotoxin active against cells expressing the human T cell growth factor receptor. [PDF]
David J. FitzGerald+3 more
openalex +1 more source
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit+19 more
wiley +1 more source
LAT The ZAP-70 Tyrosine Kinase Substrate that Links T Cell Receptor to Cellular Activation
Weiguo Zhang+4 more
semanticscholar +1 more source
This article advocates integrating temporal dynamics into cancer research. Rather than relying on static snapshots, researchers should increasingly consider adopting dynamic methods—such as live imaging, temporal omics, and liquid biopsies—to track how tumors evolve over time.
Gautier Follain+3 more
wiley +1 more source
Legumain deficiency halts atherogenesis by modulating T cell receptor signaling. [PDF]
Xiang X+8 more
europepmc +1 more source
Microglia act as tumor suppressors during brain metastasis colonization but shift to a tumor‐promoting role after melanoma brain metastases form. NF‐κB/RelA signaling emerges as a key driver of this phenotypic shift. Targeting this pathway reprograms microglia into a pro‐inflammatory state, enhancing antitumor immunity and immune checkpoint inhibitor ...
Noam Savion‐Gaiger+2 more
wiley +1 more source
Pre-T cell receptor-α immunodeficiency detected exclusively using whole genome sequencing. [PDF]
Merico D+11 more
europepmc +1 more source
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu+11 more
wiley +1 more source